speaker-icon

Latest Posts

Partex-Lupin-press-release-illustration

23

Apr 24

Partex Partners with Lupin to Revolutionize Drug Discovery through AI-Driven Asset Search and Evaluation

Frankfurt, Germany, 23 April 2024 – Partex, a leading provider of AI-driven solutions in the pharmaceutical industry, is thrilled to...
Read More
Partex-NV-announces-collaboration-with-Althea-DRF-Lifesciences

28

Mar 24

Partex NV announces collaboration with Althea DRF Lifesciences to provide comprehensive end-to-end services to accelerate drug discovery and development

Frankfurt, Germany; 28 March 2024 – Partex Group, a pioneer in AI-driven drug discovery, announces a collaboration with Althea DRF...
Read More

Innoplexus wins Horizon Interactive Gold Award for Curia App

Read More

Author name: Lawrence Ganti

Lawrence Ganti is the Global President of Life Sciences, CEO of  Americas, and Member of the Global Executive Community. Prior to joining Innoplexus, Lawrence spent 15 years leading teams across functions and geographies in the pharmaceutical industry. He also worked as a research associate for McKinsey & Company and holds an MBA from IMD in Switzerland and a bachelors from Babson College in the United States.

Drug-Discovery

Leveraging AI for Drug Discovery in early stage Biotech Companies

Many biotech firms lack the basic data infrastructure to properly exploit digital tools and AI-technologies like machine learning, computer vision, entity normalization, network analysis, etc, and they don’t employ their own data scientists. However, some investors are specifically looking at biotech companies combining the DNA of both pharmaceutical and digital technology groups. Funding is only …

Leveraging AI for Drug Discovery in early stage Biotech Companies Read More »

artificial-intelligence

To unlock innovation, pharma needs to be honest about failure

Many successful leaders agree that a company’s willingness to embrace and learn from failure can unlock innovation – and it’s a lesson the pharmaceutical industry would do well to learn. Take Jeff Bezos, for example. As the CEO of Amazon, he encourages designing bold experiments that may lead to failure. After Amazon acquired Whole Foods, …

To unlock innovation, pharma needs to be honest about failure Read More »

why-data-analytics

Why data analytics should be Pharma’s new core competency

Defining your company’s core competency—what you do really well—can set you apart and secure a trajectory of success. Pharma’s core competency has evolved over the years. Initially, it was research and companies that were fortunate enough to discover major blockbuster drugs enjoyed profitable periods of market exclusivity. However, once the pharma market consolidated into large …

Why data analytics should be Pharma’s new core competency Read More »

machine-learning

Why machines need to speak the language of Life Sciences

Do you remember the days when NLP, known as Neuro-Linguistic Programming was all the rage in self-help books and motivational speaking? You remember the self-help gurus preaching the use of Neuro-Linguistic Programming as a method to help you achieve near superpowers to attain your goals by “modelling” the skills of so-called exceptional people. Well, since …

Why machines need to speak the language of Life Sciences Read More »